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Non-coding RNAs (ncRNAs) can be divided into circular non-coding RNAs (circRNAs) 
and linear ncRNAs. ncRNAs exist in different cell types, including normal cells, tumor 
cells and immunocytes. Linear ncRNAs, such as long ncRNAs and microRNAs, have 
been found to play important roles in the regulation of tumor immunity and immunother-
apy; however, the functions of circRNAs in tumor immunity and immunotherapy are less 
known. Here, we review the current status of ncRNAs in the regulation of tumor immunity 
and immunotherapy and emphatically discuss the potential roles of circRNAs as tumor 
antigens in the regulation of tumor immunity and immunotherapy.
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iNTRODUCTiON
Non-coding RNAs (ncRNAs), mainly including microRNAs (miRNAs), long non-coding RNAs 
(lncRNAs), and circular RNAs (circRNAs), constitute approximately 95% of total RNAs in eukaryotic 
cells (1) and have important physiological functions in gene regulation (2). An increasing number of 
studies have shown that the roles of ncRNAs in tumorigenesis and tumor immunity are complicated 
and significant (3, 4). As a novel type of ncRNA, circular RNAs were first found in RNA viruses 
approximately 40 years ago and were thought to be a result of RNA splicing errors (5, 6). However, in 
this century, the vital functions of circRNAs in eukaryotes have increasingly come to light. Recently, 
with the development of RNA sequencing, thousands of types of circRNAs have been found to be 
endogenous in mammalian cells and to be stable and abundant (6). Various physiological functions 
are associated with circRNAs, such as acting as miRNA sponges (7–9) and protein translation tem-
plates (10–13) and regulation of gene expression (14–17), including expression of the parental genes 
(18). In addition, circRNAs are abundant in eukaryotes, especially in the central nervous system 
(19, 20), and are involved in many diseases, including different cancers (21–23) and autoimmune 
diseases (24, 25).
Abbreviations: APCs, antigen-presenting cells; CDK2, cyclin-dependent kinase 2; circRNAs, circular RNAs; CRCC, 
colorectal cancer cells; CTLA4, cytotoxic T  lymphocyte-associated antigen 4; CTLs, cytotoxic T cells; DCs, dendritic cells; 
DNMT, DNA methyltransferase; ElciRNA, exon-intron circular RNAs; EZH2, enhancer of zeste homolog 2; FDA, Food and 
Drug Administration; HLA, human leukocyte antigen; IL, interleukin; IFNs, interferons; LCR, locus control region; lncR-
NAs, long non-coding RNAs; MHC, major histocompatibility complex; miRNAs, microRNAs; MVs, microvesicles; m6A, 
N6-methyladenosine; NSCLC, non-small cell lung cancer; ncRNAs, non-coding RNAs; NK cells, natural killer cells; PDA, 
pancreatic ductal adenocarcinoma; PRC2, polycomb repressive complex 2; PD-1, programmed cell death protein 1; RISC, 
RNA-induced silencing complex; TAA, tumor-associated antigens; T-ALL, T cell acute lymphoblastic leukemia; Th, T helper; 
Treg cells, regulatory T cells; T-Vec, talimogene laherparepvec.
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The ability of the immune system to fight tumors was first 
discovered by Dr. William Coley in the 19th century. He used 
Coley’s toxins to trigger an immune response and treat patients 
with various types of inoperable carcinomas, especially sarcomas 
(26). Over time, tumor immunotherapy has become increasingly 
popular, including cellular therapies, checkpoint blockades, 
tumor vaccines, and cytokines (27). However, immunotherapy 
is not satisfactory as a result of tumor heterogeneity, and side 
effects still exist (26). Although the functions of ncRNAs in tumor 
immunity have become better known, especially miRNAs (28), 
the roles of ncRNAs (circRNAs in particular) in tumor immunity 
remain unclear at present. Here, we reviewed the current status 
of ncRNAs in tumor immunity, emphatically discuss the potential 
roles of circRNAs in regulating the immunity regulation.
Current Status of Antitumor immunity  
of Linear ncRNAs
Tumor immunity requires T cells and dendritic cells (DCs) to achieve 
antitumor effects (27). First, tumor cells secrete tumor antigen 
concomitant with tumor growth. Then, DCs capture the antigens 
to stimulate antigen-specific T cells through major histocompat-
ibility complex (MHC) classes I and II. Human MHC molecules are 
also called human leukocyte antigen (HLA). MHC class I activates 
CD8+ cytotoxic T  cells (CTLs), whereas MHC class II activates 
CD4+ helper T cells. Helper T cells are divided into four types (Th0, 
Th1, Th2, and Th3). Th1 cells have multiple functions involving the 
secretion of cytokines, including interleukin (IL)-2 and interferons 
(IFNs), to promote CTL proliferation and CTL-mediated immune 
responses, whereas Th2 cells produce cytokines, such as IL-6, which 
stimulate B cell proliferation (27). Finally, through the regulation of 
helper T cells and other cells, CD8+ CTLs and natural killer (NK) 
cells are activated to exert the antitumor effect (27, 29).
Although the immune system responds to tumor cells, 
other factors are also involved throughout the process, includ-
ing suppressor immune cells [such as regulatory T  cells (Treg 
cells), myeloid-derived suppressor cells, and tumor-associated 
macrophages], epigenetic modifications, and checkpoints. 
Studies have shown that the median ratio of Tregs-to-oTLs 
(overall T lymphocytes) increases from 3 to 8% in healthy tissues 
to 18–25% in all tumor entities and that Tregs suppress effector 
T lymphocytes to fight tumors (30). Epigenetic silencing of the 
Th1-type chemokines CXCL9 and CXCL10 through mechanisms 
such as enhancer of zeste homolog 2 (EZH2)-mediated histone 
H3 lysine 27 trimethylation and DNA methyltransferase (DNMT) 
1-mediated DNA methylation reduces effector T cell trafficking 
to the tumor microenvironment (31). A similar phenomenon was 
also observed for polycomb repressive complex 2 (PRC2) in colon 
cancer (32). The immune system is complicated and thus needs 
checkpoints to prevent autoimmunity, such as cytotoxic T lym-
phocyte-associated antigen 4 (CTLA4, CD152) and programmed 
cell death protein 1 (PD-1) (27). CTLA4 originates from the 
CD28 receptor family and is an inhibitory molecule expressed on 
the T cell surface that activates these cells by delivering inhibitory 
signals and competing with the T cell activation molecule CD28 
for binding to CD80 (B7.1) and CD86 (B7.2) (33–35). PD-1 is also 
a member of the B7/CD28 family and is expressed on activated 
T cells, leading to negative regulation of lymphocyte activation 
(27). PD-1 binding to its ligands PD-L1 (B7-H1, CD274) and 
PD-L2 (B7-DC; CD273) inhibits the activation of the PI3K/AKT 
and Ras/MEK/ERK pathways to decrease T cell proliferation and 
apoptosis and suppresses cytokine production and glycolysis 
to reprogram the supersession of activated T cells (27, 36, 37). 
ncRNAs (especially miRNAs) can also regulate T  cell develop-
ment, function, and aging; for instance, miR-21, miR-155, and 
miR-17–92 regulate T cell activation, which miRNAs are called 
Immuno-miRs (38). In tumor immunity, although linear ncRNAs 
are a research hotspot (especially miRNAs and lncRNAs), and 
are essential for the pathyological activities of immunocytes in 
tumors, not all of their functions are clearly understood.
miRNAs and Antitumor Immunity
Some studies have shown that dysregulation of certain miRNAs 
in cancer cells contributes to immune privilege (39). In glioma, 
miR-15a/16 deficiency can result in infiltration by CD8+ CTLs 
and inhibit tumor growth through targeting mTOR (40). In 
melanoma cells with downregulation of miR-211, the potential 
target of miR-211 (preferentially expressed antigen of melanoma 
protein) is overexpressed (41). In 2014, Xie et  al. found that 
miR-20a was overexpressed in human ovarian cancer tissues, 
which decreased NK cell cytotoxicity through binding directly to 
the 3′-untranslated region of the MICA/B mRNA. This binding 
cleaved the mRNA and thus reduced MICA/B protein expression; 
these proteins are ligands of the natural killer group 2 member D 
receptor that is found on NK cells, macrophages, γδ(+) T cells, 
and CD8(+) T cells and thus resulted in immune privilege (42). 
miR-133a, which controls HLA-G protein stability, is decreased 
in ovarian, prostate, and bladder cancer, whereas miR-148/152, 
which also regulate HLA-G, are downregulated in hepatocellular 
carcinoma and gastrointestinal cancers (29). miR-487b suppresses 
IL-33 mRNA and protein expression during the differentiation of 
bone marrow-derived macrophages (43). The miR-17-92 cluster 
promotes CD4+ T cell activation, survival, proliferation, and Th1 
differentiation but inhibits Th2 and iTreg differentiation (44).
MicroRNAs also exert regulatory functions through tumor-
derived exosomes and microvesicles (MVs) (45, 46). In exosomes 
from nasopharyngeal carcinoma cells, hsa-miR-24-3p, hsa-miR-
891a, hsa-miR-106a-5p, hsa-miR-20a-5p, and hsa-miR-1908 are 
overexpressed and downregulate the MARK1 signaling pathway 
to alter T cell proliferation and differentiation and even promote 
T  cell dysfunction (45). miR-214, which is secreted by human 
cancers, can be delivered into recipient T cells via MVs and pro-
mote tumor growth, including downregulating the phosphatase 
and tensin homolog, promoting Treg expansion, inducing Treg 
cells to secret high levels of the immunosuppressive cytokine 
IL-10, and preventing MHC type II molecule expression by 
T cells (46). Thus, miRNAs can regulate the expression of tumor 
antigen in tumor cells, regulate immunocyte viability, including 
CTLs, NK cells, DCs, Th cells, and Treg cells, and even regulate 
cytokines through tumor-secreted exosomes and MVs.
lncRNAs and Antitumor Immunity
Long ncRNAs are defined as ncRNAs with over 200 nucleotides 
with no protein-coding capacity (47). lncRNAs regulate gene 
expression at the epigenetic (XIST, ANRIL, HOTAIR, and 
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HOTTIP), transcriptional (7SK, SRA, PCAT-1, and GAS5) and 
posttranscriptional (MALAT1, 1/2-sbsRNAs, NEAT) levels 
through interacting with different types of molecules, such as 
miRNAs, mRNAs, and even proteins (48–50). lncRNAs are differ-
entially expressed between various tissues or developmental stages 
and participate in the physiological activities of normal cells, tumor 
cells, and cells involved in different diseases. They act as scaffolds to 
bridge different molecules [e.g., HOTAIR can bind PRC2 and the 
LSD1–CoREST complex to recruit chromatin-modifying factors 
(50)], as a part of ribonuceloproteins [e.g., lncRNA-Cox2 binds 
hnRNP-A/B and hnRNP-A2/B1 to regulate immune gene expres-
sion (51)], and miRNA sponges [e.g., H19 functions as a miRNA 
sponge for miR-138 and miR-200a to promote the epithelial to 
mesenchymal transition in colorectal cancer (52)].
The expression of lncRNAs has been studied in immunocytes. 
CD11c+ DCs express lncRNAs when stimulated with lipopoly-
saccharide, whereas CD8+ and CD4+ T cells express hundreds of 
lncRNA genes that are specific and play roles during differentia-
tion or activation (47, 53–57). Hu et al. identified 1,524 lncRNAs 
in 42 T  cell samples ranging from early T  cell progenitors to 
terminally differentiated T helper (Th) subsets. The authors found 
that STAT4 activated the expression of Th1-preferred lncRNAs, 
whereas STAT6 activated the expression of Th2-preferred lncR-
NAs (53). Th2-locus control region (LCR) lncRNAs, which are 
lncRNAs clustered close to the Th2 LCR, are vital for the ability of 
Th2 cells to express IL-4, IL-5, and IL-13 by establishing histone 
H3K4Me marks at the IL-4, IL-5, and I-13 promoters and recruit-
ing enzymes to alternatively splice the transcripts (53).
Many lncRNAs colocalize with protein-coding genes that 
are highly enriched in immune functions. For instance, LincR-
Ccr2-5′ AS facilitates Th2 cell migration through regulating the 
expression of Ccr genes via a mechanism that is distinct from 
the modulation of chromatin accessibility or Pol II recruitment 
(54). The RNA helicase DEAD-box protein 5 can function as a 
transcriptional co-activator and interact with RORγt to coordi-
nate the transcription of selective Th17 genes (i.e., IL-17a, IL-17f, 
and IL-22); however, its function depends on a conserved nuclear 
Rmrp (56). The lncRNA-CD244 recruits polycomb protein EZH2 
to the infg/tnfa promoters and mediates H3K27 trimethylation 
at the infg/tnfa loci to inhibit IFN-γ/TNF-α expression in CD8+ 
cell (55, 57). In Treg cells, lnc-Smad3 interacts with the histone 
deacetylase HDAC1 and contributes to epigenetic modifications, 
thereby silencing the expression of Smad3, which can mediate 
signals from the transforming growth factor beta superfamily 
ligands to regulate cell activity (57).
Apart from T cells, lncRNAs also dominate the regulation of 
gene expression in B cells (58). Researchers have found that most 
lncRNAs identified in B cells are substantially different from those 
identified in other immunocytes and that 20% of these lncRNAs 
can associate with enhancer or promoter regions to regulate gene 
transcription (58). For example, LNCGme00432, LNCGme00344, 
and LNCGme00345, which are bound by the transcription fac-
tor PAX5, are located close to the B  cell lymphoma 11a gene, 
which is vital for B cell development, and thus allow Bcl11a to 
be regulated by PAX5 (58). The interactions of lncRNAs and 
immunocytes have also been studied in leukemia (58–60). In 
human T cell acute lymphoblastic leukemia (T-ALL), the lncRNA 
LUNAR1 is regulated by the Notch pathway and is necessary for 
efficient T-ALL growth through enhancement of IGF1R mRNA 
expression (59). Additionally, the lncRNA NALT functions as a 
transcription factor in pediatric T-ALL to activate the NOTCH 
signal pathway and promote cell proliferation (60).
Current Status of immunotherapy  
with Linear ncRNAs
Although the immune response can fight tumors, tumors can 
escape immune surveillance through decreasing the expression of 
tumor antigens and/or inhibiting the functions of CTLs and DCs. 
Consequently, researchers have increasingly focused on tumor 
immunotherapies, such as CAR T cell adoptive immunotherapy, 
immune checkpoint blockade therapy, cancer vaccines, and onco-
lytic virus therapy (27, 61, 62). Some of these therapies are related 
to regulation by linear ncRNAs, although research is limited.
The Progress and Confusion of CAR T Cell  
Adoptive Therapy
CAR T  cell adoptive therapy is a technique that uses adoptive 
cell transfer to treat cancer (61). To achieve this goal, researchers 
redirect T cell killing to cells expressing the antibody’s cognate 
antigen through transducing T cells with chimeric genes encod-
ing single-chain antibodies linked to a transmembrane region 
and an intracellular domain that encode the signaling adaptor 
for the T  cell receptor (Figure  1A). CD19-targeted CAR T 
was an effective modality for the treatment of refractory B cell 
malignancies, including acute and chronic lymphatic leukemia 
and Hodgkin’s and non-Hodgkin’s lymphomas, in a series of clini-
cal studies (63). However, extending this approach to allogeneic 
T cells has not been satisfactory, because this therapy may carry 
a significant risk of inducing graft-versus-host disease; the use 
of cord blood NK cells engineered to express IL-15 can improve 
this limitation (64). However, many problems still exist for solid 
tumors, including physical barriers, the immunosuppressive 
tumor microenvironment, and specificity and safety (65). To 
solve these problems, researchers have focused on finding novel 
targets for CAR T cell therapy for solid tumors, including the use 
of CD70 as the target for gliomas (66) or choosing combination 
therapy, which will be discussed later.
The Advantages and Disadvantages of Immune 
Checkpoint Therapy
Immune checkpoint therapy is a therapy that uses antibodies 
that block checkpoints, such as the CTLA-4 and PD-1 pathways 
(Figure  1B). In 2011, the US Food and Drug Administration 
(FDA) approved anti-CTLA-4 antibodies (ipilimumab) for 
use in treating melanoma (61). Additionally, pembrolizumab 
and nivolumab, which inhibit the PD-1 pathway, have been 
approved by the FDA for the treatment of ipilimumab-refractory 
melanoma. Nivolumab is also an anti-PD-1 monoclonal antibody 
used for the treatment of Hodgkin’s lymphoma. In addition, 
MPDL-3280A, which is an anti-PD-L1 monoclonal antibody, is 
used for the treatment of bladder cancer and non-small cell lung 
cancer (NSCLC) (67).
Some patients who receive immune checkpoint therapy have 
durable and gratifying responses. However, until now, a majority 
FigURe 1 | Current immunotherapy research. (A) CAR-T cell therapy indicates that T cells collected from cancer patients are genetically engineered to identify the 
tumor antigens and activate T cells to achieve the effect of antitumor immunity; (B) immune checkpoint therapy blocks programmed cell death protein 1 (PD-1) or 
cytotoxic T lymphocyte-associated antigen (CTLA4). PD-1 binds to PD-L1 to inhibit protein-tyrosine phosphatase-2 (SHP-2), which is involved in CTL activation. 
Pembrolizumab or nivolumab can block PD-1, allowing SHP-2 to strengthen the antitumor immunity. CTLA4 competes with CD28 for binding to CD80/86 to 
activate T cells. After blocking CTLA4 with ipilimumab, CD28 can bind to CD80/86 to help activate T cells and strengthen antitumor immunity; (C) cancer vaccine 
therapy includes using tumor-associated antigens (TAA) or a tumor-associated virus to activate antigen-presenting cells (APCs), such as dendritic cells (DCs), or to 
activate cytotoxic T cells (CTLs) to assist antitumor immunity or genetically engineering tumor cells to make them express immune stimulatory cytokines, such as 
GM-CSF, to stimulate anti-tumor immunity; (D) oncolytic virus therapy indicates that oncolytic viruses can kill tumor cells or enhance the identification of their 
presented antigens by APCs to assist with antitumor immunity.
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of patients cannot respond to immune checkpoint inhibition 
in the histologies tested (68). The KEYNOTE-061 pembroli-
zumab in Phase III trials for patients with advanced gastric or 
gastroesophageal junction adenocarcinoma may not improve 
the overall survival and progression free survival, even in the 
PD-L1 positive population (69). Among patients with previously 
untreated stage IV or recurrent NSCLC with a PD-L1 expression 
level of 5% or more, first-Line Nivolumab cannot provide a longer 
progression-free survival (70). The phase III KEYNOTE-183 and 
KEYNOTE-185 pembrolizumab trails for patient with multiple 
myeloma are not satisfied. And Merck announced that it was 
postponing enrollment in them (71). It seems that not all of 
immune checkpoint therapy is effective and the mechanism of 
immune checkpoint is still not clear enough. And if a patient 
receiving immune checkpoint therapy has disease recurrence, the 
future treatment will be unclear enough (72). Besides, blocking 
the immune system’s natural inhibitory mechanisms will bring 
unpredictable side-effects which have manifested clinically as 
diarrhea, rash, and hepatitis (72). ncRNAs can play vital roles 
in immune checkpoints. miR-138 suppresses CTLA-4 and PD-1 
expression in CD4+ cells, which are involved in the anti-glioma 
efficacy (73). Cortez et al. proved that PD-L1 was regulated by p53 
via miR-34 (p53/miR-34/PD-L1 axis) in lung cancer, which might 
assist in the development of a therapy against this cancer (74).
The Progress and Limitations of Cancer Vaccine 
Therapies
Cancer vaccines can promote tumor-specific immune responses, 
especially for CD8+ CTLs specific for tumor antigens. Cancer 
vaccines generate antitumor immunity through administration 
5Xu et al. circRNA in Antitumor Immunity
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of tumor antigens with antigen-presenting cells (APCs), includ-
ing DCs, B  cells, and monocytes. The tumor antigens include 
overexpressed antigens, cancer-testis antigens, oncofetal anti-
gens, and mutated antigens (75). There are four types of cancer 
vaccines: peptide-based strategies (through the delivery of MHC 
class I-restricted peptide epitopes derived from tumor-associated 
antigens to activate rare specific CD8+ T cell clones), APC-based 
strategies (e.g., DCs are the most effective APCs; mononuclear 
cells from autologous patients are cultured in  vitro to induce 
the formation of DCs and then loaded with tumor antigen and 
used to treat patients), tumor-based strategies [through killing 
and engineering tumor cells to express immunostimulatory 
cytokines, such as granulocyte-macrophage colony-stimulating 
factor (GM-CSF), to stimulate antitumor immunity] and virus-
based strategies (75) (Figure 1C). However, the effects of cancer 
vaccines are limited due to the immunosuppressive effects of the 
tumor microenvironment and the difficulty in specifically select-
ing target antigens (75, 76).
The Present Situation for Oncolytic Virus Therapy
Oncolytic viruses are viruses that selectively replicate in cancer 
cells and kill them without harming normal tissues. These 
viruses can be genetically engineered or naturally occurring (62) 
(Figure  1D). Talimogene laherparepvec (T-Vec) is a second-
generation oncolytic herpes simplex virus type 1 (HSV-1) that is 
armed with GM-CSF to treat malignant melanoma; this virus was 
first shown to be an oncolytic viral drug in the USA and Europe. 
Other viruses, including JX-594 for hepatocellular carcinoma, are 
still in clinical trials. In Japan, G47 (a third-generation oncolytic 
HSV-1) was used in research to treat glioblastoma patients. The 
main feature of these viruses is the induction of specific antitumor 
immunity during specific viral replication steps. For example, 
genetically engineered oncolytic viruses, such as T-Vec and G47, 
contain a deletion in the α47 gene, whose product can inhibit the 
transporter associated with antigen presentation. Therefore, APC 
processing will be facilitated by injecting an engineered oncolytic 
virus, and cancer cells will be more easily attacked by the immune 
system (62). There are significant effects for some patients with 
melanoma treated by T-Vec, but the safety of oncolytic viruses is 
still concerned (77, 78). They are live viruses with the possibility 
of proliferating upon clinical administration. Besides, they can 
induce host antiviral immune responses and for immunocom-
promised patients, it may be not an appropriate therapy but 
even harmful (77). At last, researches showed that this therapy 
is much slower than therapeutic agents that directly kill tumor 
cells (77). In oncolytic virus therapy, miRNA target sequences 
can be incorporated to control exogenous gene expression and 
viral tropism in different tissues as a mechanism to enhance the 
therapeutic effect of oncolytic viruses and thus reduce toxicities 
in nontarget tissues (79).
Combination Immunotherapy
Due to the limitations of these different immunotherapies, 
researchers have begun to focus on combination immunotherapies 
to strengthen treatment effects. For example, in prostate cancer 
models, adoptive human prostate-specific membrane antigen-
CAR T cell immunotherapy was enhanced when combined with 
a PD-1 blockade, but the treatment response had a relatively 
short duration (80). In pancreatic ductal adenocarcinoma 
(PDA), PD-L1 was weakly expressed in untreated human and 
murine PDAs. Treatment with a granulocyte macrophage colony-
stimulating factor-secreting PDA vaccine (GVAX) upregulated 
PD-L1 membranous expression. Treatment of tumor-bearing 
mice with combination therapy including a vaccine and PD-1 
antibody blockade improved murine survival compared with 
PD-1 antibody monotherapy or GVAX therapy alone (81). In 
colon and ovarian cancer models, injection of the oncolytic vac-
cinia virus vvDD attracted effector T cells and induced PD-L1 
expression by both cancer and immune cells in the tumor. The 
combination of an oncolytic vaccinia virus and the PD-L1 block-
ade reduced PD-L1-positive cells and promoted non-redundant 
tumor infiltration of effector T cells and, therefore, enhanced the 
therapeutic efficacy (82). Moreover, because linear ncRNAs have 
their own functions in different immunotherapies, focusing on 
the use of ncRNAs to aid immunotherapies has great potential. 
However, the relationship between ncRNAs and immunotherapy 
remain unclear.
Functions of circRNAs
Since circRNAs became a field of interest for researchers, several 
reviews have examined the functions of circRNAs. These func-
tions can be divided into four parts: working as miRNA sponges 
to inhibit their functions, interacting with proteins to regulate 
gene expression, regulating gene expression, and regulation 
protein translation (1, 83–85).
circRNAs As miRNA Sponges
circRNAs were demonstrated to function as miRNA sponges 
in 2013, especially ciR-7 (also named CDR1as) and sex-
determining region Y (Sry) (7). ciR-7 contains more than 70 
selectively conserved miRNA target sites that can bind miR-7, 
facilitate a specific miR-7-AGO2 interaction, and suppress 
miR-7 activity in diseases including hepatocellular carcinoma, 
colorectal cancer, and diabetes (7, 86–88). The circRNA Sry, 
which is specific to the mouse testes, has 16 binding sites for 
miR-138 (7). Over time, more circRNAs have been identified 
as miRNA sponges, including circMTO1 as a miR-9 sponge in 
hepatocellular carcinoma (89), cir-ZNF609 as a miR-145 sponge 
in bowel tissues with Hirschsprung disease (90), and CircBIRC6 
as a sponge for miR-34a and miR-145 in human embryonic stem 
cells (91).
circRNA Binding to Proteins
Scientific reports have shown that circRNAs can bind proteins to 
perform physiological functions. Du et al. found that circFoxo3 
was able to bridge cyclin-dependent kinase 2 (CDK2) and p21 to 
influence the cell cycle (14). In addition to bridging CDK2 and 
p21, circFoxo3 has similar functions in the interaction between 
MDM2 and p53 (14). By binding to both proteins, circ-Foxo3 
promoted MDM2-induced p53 ubiquitination and facilitated p53 
degradation. circANRIL, which directly interacts with pescadillo 
homolog 1, can prevent the maturation of ribosomal RNA (16). 
CircPABPN1 was confirmed to bind to HuR and suppress its 
binding to the PABPN1 mRNA (15). Besides, circAmotl1 was 
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proven to bind to PDK1 and AKT1 to lead to AKT1 phosphoryla-
tion and nuclear translocation in human cardiac tissue (92).
circRNAs Regulate Gene Expression
Although the regulation of gene expression through the miRNA 
sponge function of circRNAs has been more widely studied, 
circRNAs have also been reported to modulate gene expression 
both transcriptionally and posttranscriptionally.
circRNAs Regulate Gene Transcription
Circular RNAs can influence gene transcription through direct 
and indirect mechanisms. For example, the exon-intron circular 
RNAs (ElciRNA) circEIF3J and circPAIP2 have cis regulatory 
effects on their parental genes EIF3J and PAIP2 and facilitate their 
expression through interacting with Pol II, U1 snRNP, and their 
parental gene promoters (18). The circRNAs ci-ankrd52 and ci-
sirt7 have functions similar to circEIF3J and circPAIP2 as positive 
regulators through their interactions with Pol II (93). All of these 
circRNAs modulate gene transcription as a transacting element.
Some circRNAs can influence other proteins to enter the 
nucleus and regulate gene transcription, such as circAmotl1 
(94, 95). circAmotl1 can increase STAT3 expression and even 
increase its nuclear translocation to regulate the expression of 
mitosis-associated genes (94). In cancer cell lines, circAmotl1 
can promote nuclear c-myc expression and help this factor bind 
to gene promoters to trigger tumorigenicity (95).
circRNAs Regulate mRNA Splicing and Stability
In mouse macrophages, the LPS-inducible circRNA mcircRas-
GEF1B increases ICAM-1 expression and stabilizes mature 
ICAM-1 mRNAs (96). In plants, the circRNA derived from the 
SEP3 gene can bind strongly to its cognate DNA locus and form 
a R-loop, which can induce transcriptional pausing to regulate 
cognate mRNA splicing (97).
circRNAs As Translation Templates
circRNA belong to ncRNAs, but an increasing number of studies 
have shown that circRNAs can function as translation templates 
(10–13). In 2017, researchers showed that circ-ZNF609, which 
controlled myoblast proliferation and had a 753-nt open reading 
frame from the start codon to an in-frame stop codon, translated 
proteins through sequences able to act as internal ribosome entry 
sites (IRESs) (12). At the same time, Pamudurti et al. found that 
many circRNAs were associated with translating ribosomes based 
on ribosome footprinting and that the UTRs of these circRNAs 
could mediate cap-independent translation; for example, the 
translation of circMbl was regulated by starvation and FOXO in 
fly heads (11). A recent study confirmed that circRNA translation 
could be driven by N6-methyladenosine (m6A) (12). In normal 
human brain, circ-FBXW7 is highly expressed and translated into 
a novel 21-kDa protein termed FBXW7-185aa, which can help to 
inhibit proliferation and cell cycle acceleration in cancer cells (13).
Putative Roles of circRNAs in Antitumor 
immune Regulation and immunotherapy
Although circRNAs have been reported to contain a wealth of 
potential functionalities in tumorigenesis and the immune system, 
these functionalities are not clearly understood. In tumors, many 
circRNAs have been found to be potential biomarkers for the 
cancer diagnosis and prognosis (21, 83). hsa_circ_002059 was 
confirmed to be significantly downregulated in gastric cancer 
tissues in 2015 (98). In laryngeal squamous cell cancer tissues, 
hsa_circRNA_100855 was the most upregulated circRNA, 
whereas hsa_circRNA_104912 was the most downregulated 
circRNA (99). Moreover, circRNA networks with other ncRNAs 
in tumor cells have been increasingly studied (23). These studies 
investigating ncRNA networks are more focused on the tumor 
itself and will help elucidate how different ncRNAs work in tumor 
cells to regulate tumor development in the absence of a tumor 
environment.
Cellular circRNAs Regulate Antitumor Immunity with 
miRNAs or Proteins
The relationship between miRNAs and tumor immunity is clearer 
than the relationships for lncRNAs and circRNAs. The close rela-
tion between circRNAs and miRNAs can help circRNA partici-
pate in antitumor immunity through circRNA–miRNA–mRNA 
axis. circRNAs can be found interacting with miRNAs that 
participate in tumor immunity (Figure 2A). In 2017, the circRNA 
hsa_circ_0020397 was found to bind to miR-138, suppress miR-
138 activity, and sequentially promote the expression of miR-138 
targets, such as telomerase reverse transcriptase and PD-L1, in 
colorectal cancer cells (CRCCs) (100). Due to the high level of 
has_circ_0020397 expression in CRCCs, PD-L1 is upregulated 
and can interact with PD-1 to induce cancer immune escape. 
It seems that during immune checkpoint therapy, the change 
of circRNAs expression may influence the effect of this therapy. 
circAmotl1, which was discussed above, upregulates Dnmt3a, 
which can methylate the miR-17 promoter and decrease miR-
17-5p expression; as a result, STAT3 expression is increased and 
plays an important role in tumor-mediated immune suppression 
(94). Through bioinformatics analyses, circRNA databases [i.e., 
starBase v2.01 and circBase2 (85)] can be used to predict whether a 
circRNA can regulate tumor immunity-associated miRNAs, such 
as miR-148/152, miR-487b, and miR-17-92. Potential new tumor 
antigens may be identified based on these predictions.
Compared to the interaction of miRNAs with circRNAs, the 
interactions of circRNAs with proteins are less well understood. 
circFoxo3 binds to MDM2, which is associated with p53, to 
induce p53 degradation. In tumor stromal cells, p53 plays a key 
role in tumor development by inducing an increase in inducible 
nitric oxide synthase expression and modulating the immune 
responses (14, 101) (Figure  2B). This evidence showed that 
circRNA can modulate the stability of some proteins like p53 to 
regulate immune responses in tumor.
Exosomal circRNAs Modulate Antitumor Immunity 
with the Possibility of Tumor Antigen
Due to their stable and specific properties, circRNAs may serve 
as tumor antigens for the immune response. Chen et al. showed 
1 http://starbase.sysu.edu.cn/
2 http://www.circbase.org/
FigURe 2 | Putative roles of circular RNAs (circRNAs) in antitumor immune regulation and immunotherapy. (A) circRNAs can bind to microRNAs (miRNAs) to 
upregulate the expression of genes associated with antitumor immunity, including PD-L1 and STAT3; (B) circRNAs can bind proteins, such as MDM2 and p53, to 
regulate their stability and antitumor immunity; (C) circRNAs in tumor exosomes may be transported to immunocytes as tumor antigens to activate antitumor 
immunity or bind to miRNAs and proteins to regulate immunocyte activity; (D) circRNAs may stabilize miRNAs in exosomes when they are transported from tumor 
cells to immunocytes and then help release the miRNAs into the immunocytes.
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that transfection of purified circRNAs led to the activation of 
RIG-I, which is a nucleic acid sensor that can sense foreign cir-
cRNAs and induce innate immune gene expression (101, 102). 
Many abnormal circRNAs are produced during tumorigenesis 
due to genetic mutations and chromosomal changes. In acute 
promyelocytic leukemia, the chromosomal translocations of 
PML/RARα give rise to fusion circRNAs (103). Then, the newly 
formed abnormal circRNAs may be transported to immunocytes 
through exosomes and extracellular vesicles secreted by the 
tumor cells. In 2016, researchers reported that circRNAs were 
downregulated and transferred to exosomes from KRAS mutant 
colon cancer cells (104). In addition, the circRNAs in exosomes 
may participate in the regulation of Treg cells (105). Researchers 
have also found that circRNAs can co-precipitate with extracel-
lular vesicles (106). These studies suggest that circRNAs have 
the potential to contribute to cell-to-cell communication. 
Consequently, circRNAs may be a promising target for tumor 
immunotherapy (Figure 2C).
In addition to serving as tumor antigens, abnormal circRNAs 
may also translate proteins or polypeptides by acting as tumor 
antigens. Furthermore, abnormal circRNAs may participate in 
cell-to-cell communication and bind immune factors to regulate 
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immune activity. For example, the immune factors NF90/NF110 
can associate with intronic RNA pairs to form circRNAs, but 
these factors dissociate from circRNA-binding proteins during 
viral infections and bind to viral mRNAs to regulate antiviral 
immunity (105, 107).
Besides, circRNAs may carry other RNAs and both of them 
work as tumor antigens. Various types of miRNAs and mRNAs 
present in cancer exosomes can regulate metastasis, invasion, 
tumorigenesis, and tumor progression, such as the miR200 
family in breast cancer exosomes and miR105 in various 
cancers (108). Therefore, circRNAs may not directly regulate 
immune activity but instead may bind to miRNAs or mRNAs, 
strengthen their stability in exosomes during transportation, 
and release them when they reach the target immunocytes to 
improve their functions (Figure 2D). There is a new idea that 
circRNAs may carry tumor-specific miRNAs or mRNAs to 
transport cells to cells, which can work as a new kind of tumor 
antigens.
In addition to the involvement of exosomes secreted by cancer 
cells in antitumor immunity, exosomes secreted by stromal cells in 
the tumor microenvironment are also vital for cancer cell metastasis 
and prepossession. In 2017, Nabet et  al. showed that unshielded 
RN7SL1 RNA in exosomes secreted by stromal cells through trigger-
ing of stromal NOTCH-MYC by breast cancer cells activated RIG-I 
to induce the expression of interferon-stimulated tumor growth and 
therapy resistance (109). As reviewed previously, purified circRNAs 
are able to activate RIG-I (110) and may function similar to RN7SL1 
RNA in exosomes. These foreign circRNAs can be recognized by 
RIG-I and may activate innate immunity. Therefore, foreign circR-
NAs from tumor cells may activate immunocytes to fight tumors.
CONCLUSiON
ncRNAs, especially circRNAs, have attracted increasing attention 
from researchers worldwide. These RNAs have been confirmed to 
regulate gene expression and signaling pathways and to translate 
TABLe 1 | The relationship between linear non-coding RNAs (ncRNAs) with antitumor immunity.
Linear ncRNA RNA type Cancer type Target gene Function
miR-15a/16 microRNA 
(miRNA)
Glioma mTOR Inhabiting CD8+ T cells infiltrating into tumors
miR-211 miRNA Melanoma PRAME Inhabiting the expression of PRAME protein to escape from immunity
miR-20a miRNA Ovarian cancer MICA/B Inhibiting MICA/B expression and natural killer (NK) cytotoxicity
miR-133a miRNA Ovarian, prostate, bladder 
cancer, head and neck 
squamous cell cancer
HLA-G Inhibiting human leukocyte antigen (HLA)-G expression to help activate 
NK cells
miR-148/152 miRNA Hepatocellular carcinoma, 
gastrointestinal cancers
HLA-G Inhibiting HLA-G expression to help activate NK cells
miR-20a-5p, miR-24-3p, 
miR-106a-5p
miRNA Nasopharyngeal carcinoma MAPK1 Inhabiting the MARK1 signaling pathway to alter T cell proliferation and 
differentiation
miR-20-5p, miR-106a-50 miRNA Nasopharyngeal carcinoma TAOK3 Inhabiting the MARK1 signaling pathway to alter T cell proliferation and 
differentiation
miR-214 miRNA Breast cancer, hepatocellular 
carcinoma, non-small-cell lung 
cancer, pancreatic cancer
PTEN Inducing regulatory T cells (Treg cells) to secret interleukin (IL)-10, and 
preventing major histocompatibility complex-II expression by T cells
miR-138 miRNA Glioma CTLA-4, PD-1 Inhabiting expression of CTLA-4, programmed cell death protein 1 of 
CD4+ T cells to escape from immune checkpoint therapy




– IL4, IL5, IL13 Establishing H3K4Me marks at IL4, IL5, and IL13 promoters and distal 
regulatory elements to help Th2 cells secret cytokine
lincR-Ccr2-5′ AS lncRNA – Ccr Upregulating the expression of Ccr to facilitates Th2 cell migration
lncRNA-Rmrp lncRNA – IL-17A, IL-17F Helping DDX5-RORγt complex assembly to facilitate Th17-mediated 
inflammatory pathologies
lncRNA-CD244 lncRNA – infg/tnfa Recruiting polycomb protein (enhancer of zeste homolog 2) to infg/tnfa 
promoters to inhibits interferon-γ/TNF-α expression in CD8+ T cells
lnc-Smad3 lncRNA – Smad3 Interacting with the histone deacetylase HDAC1 to silence the expression 




lncRNA – Bcl11a Bounding with transcription factor PAX5 to regulate the expression of 
Bcl11a in B cell development
lncRNA- LUNAR1 lncRNA T cell acute lymphoblastic 
leukemia (T-ALL)
IGF1R Stimulating the expression of the IGF1R gene through chromosomal 
looping for T-ALL maintenance
lncRNA-NALT lncRNA T-ALL NOTCH1 Activating the transcription of NOTCH1 in T-ALL and promoting cell 
proliferation
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